From: Clinical implication of cellular vaccine in glioma: current advances and future prospects
Malignancy | Phase | Number | Study title | Identifier | Status | Interventions | Observation |
---|---|---|---|---|---|---|---|
DC vaccine | |||||||
 Malignant glioma | I | 35 | Surgical resection with gliadel wafer followed by dendritic cells vaccination for malignant glioma patients (Gliadel Wafer) | NCT00576446 | Completed | NA | PFS |
 Malignant glioma | I | 8 | Vaccine therapy in treating patients with malignant glioma | NCT00612001 | Completed | GAA pulsed DC | Toxicity; PFS; OS |
 Recurrent malignant glioma | I/II | 22 | Vaccination-dendritic cells with peptides for recurrent malignant gliomas | NCT00766753 | Completed | GAA pulsed DC | Toxicity; PFS; OS |
 Recurrent GBM | I | 20 | A Study of ICT-121 dendritic cell vaccine in recurrent glioblastoma | NCT02049489 | Completed | CD133 pulsed DC | Toxicity; feasibility; PFS; OS |
 Recurrent GBM | I | 50 | Vaccine therapy in treating patients undergoing surgery for recurrent glioblastoma multiforme | NCT00890032 | Completed | BTSC mRNA-loaded DC | Toxicity; feasibility; humoral and cellular immune responses |
 Malignant glioma | I | 71 | Dendritic cell vaccine with imiquimod for patients with malignant glioma | NCT01792505 | Completed | Imiquimod adjuvant | Toxicity; PFS |
 Malignant glioma | I | 6 | Nivolumab with DC vaccines for recurrent brain tumors (AVERT) | NCT02529072 | Completed | Nivolumab adjuvant | Toxicity; PFS; OS |
 IDH1(R132H) mutant glioma | I | 30 | Safety and efficacy of IDH1 R132H-DC vaccine in gliomas | NCT02771301 | Recruiting | IDH1(R132H) DC | IDH1(R132H) specific T cells; anti-IDH1(R132H) antibody level |
 Newly diagnosed GBM | I | 10 | Personalized cellular vaccine for glioblastoma (PERCELLVAC) | NCT02709616 | Active, not recruiting | TAA pulsed DC | Toxicity; PFS; OS; CD8 + and CD4 + T cell response |
 Recurrent GBM | I | 10 | Personalized cellular vaccine for recurrent glioblastoma (PERCELLVAC2) | NCT02808364 | Active, not recruiting | TAA pulsed DC | Toxicity; PFS; OS; CD8 + and CD4 + T cell response |
 HGG | I | 11 | Cytomegalovirus (CMV) RNA-pulsed dendritic cells for pediatric patients and young adults with WHO grade IV glioma, recurrent malignant glioma, or recurrent medulloblastoma (ATTAC-P) | NCT03615404 | Active, not recruiting | CMV RNA-pulsed DC | Toxicity |
 Pediatric HGG | I | 8 | Adoptive cellular therapy in pediatric patients with high-rade gliomas (ACTION) | NCT03334305 | Recruiting | GM-CSF and TTRNA-xALT plus Td vaccine without autologous HSCs | Toxicity; PFS; OS; INF γ secretion |
 DIPG | I | 21 | Brain stem gliomas treated with adoptive cellular therapy during focal radiotherapy recovery alone or with dose-intensified temozolomide (Phase I) (BRAVO) | NCT03396575 | Recruiting | GM-CSF and TTRNA-xALT plus Td vaccine without autologous HSCs | Toxicity; feasibility; PFS; OS; immune responses |
 GBM; anaplastic astrocytoma | I | 20 | Dendritic cell (DC) vaccine for malignant glioma and glioblastoma | NCT01808820 | Active, not recruiting | Post-DC Vaccine therapy, administered lysate of tumor | Toxicity; PFS; OS; MDSC levels and blood counts |
 Newly diagnosed GBM | I | 42 | Vaccine therapy in treating patients with newly diagnosed glioblastoma multiforme (ATTAC) | NCT00639639 | Active, not recruiting | pp65-shLAMP DC and Td | Toxicity; feasibility; PFS; OS; humoral and cellular immune responses |
 GBM | I | 39 | Phase I study of a dendritic cell vaccine for patients with either newly diagnosed or recurrent glioblastoma | NCT02010606 | Active, not recruiting | Bevacizumab adjuvant | Toxicity; PFS; OS; cytotoxic T cell activity; tumor stem cell antigen expression |
 GBM; DIPG | I | 10 | Immune modulatory DC vaccine against brain tumor | NCT03914768 | Enrolling by invitation | Cyclophosphamide and bevacizumab adjuvant | Toxicity; tumor response; PFS; OS |
 GBM | I/II | 10 | Dendritic cell vaccination for patients with solid tumors | NCT01291420 | Enrolling by invitation | WT1 mRNA-electroporated DC | Immunogenicity |
 Pediatric glioma | I | 1 | Dendritic cell vaccine therapy with in situ maturation in pediatric brain tumors | NCT01902771 | Terminated | Post-Vaccine, lysate of tumor and imiquimod adjuvant | Toxicity; feasibility; PFS; OS; immune response |
 Medulloblastoma; PNET | I/II | 1 | Phase I/II: decitabine/vaccine therapy in relapsed/refractory pediatric high grade gliomas/medulloblastomas/CNS PNETs | NCT02332889 | Terminated | GM-CSF and Poly-ICLC adjuvant | Tolerability |
 Newly diagnosed GBM | II | 11 | Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme | NCT00323115 | Completed | NA | Toxicity; tumor response; PFS; OS; T Cell immune responses |
 Newly diagnosed GBM | II | 120 | Vaccine therapy for the treatment of newly diagnosed glioblastoma multiforme (ATTAC-II) | NCT02465268 | Recruiting | pp65-shLAMP DC with GM-CSF and Td | PFS; OS; cytokine |
 Newly diagnosed MGMT unmethylated HGG | II | 48 | Immunotherapy targeted against cytomegalovirus in patients with newly-diagnosed WHO grade IV unmethylated glioma (I-ATTAC) | NCT03927222 | Recruiting | pp65-shLAMP DC with GM-CSF and Td | Toxicity; migration; OS |
 GBM | II | 100 | Study of DC vaccination against glioblastoma | NCT01567202 | Recruiting | Glioma stem-like cells (A2B5+) loaded DC | Tumor response; PFS; OS |
 Primary GBM | II | 24 | A Phase II, randomized, Open-Label, parallel-group study to evaluate the efficacy and safety of autologous dendritic cell vaccination (ADCV01) as an Add-On treatment for primary glioblastoma multiforme (GBM) patients | NCT04115761 | Recruiting | NA | PFS |
 GBM | II/III | 60 | Dendritic cell immunotherapy against cancer stem cells in glioblastoma patients receiving standard therapy (DEN-STEM) | NCT03548571 | Recruiting | NA | PFS; OS; immune responses |
ADCTA | |||||||
 Malignant glioma | I | 28 | Vaccine therapy in treating patients with malignant glioma | NCT00068510 | Completed | NA | Toxicity; tumor response; OS; immune responses |
 Pediatric malignant glioma | I | 7 | Vaccine therapy in treating young patients who are undergoing surgery for malignant glioma | NCT00107185 | Completed | NA | Toxicity; PFS; OS |
 Malignant glioma | I | 8 | Vaccination with dendritic cells loaded with brain tumor stem cells for progressive malignant brain tumor | NCT01171469 | Completed | Imiquimod adjuvant | Toxicity; tumor response |
 Newly diagnosed GBM | I | 21 | Vaccine therapy and temozolomide in treating patients with newly diagnosed glioblastoma | NCT01957956 | Active, not recruiting | NA | Toxicity; tumor response; PFS; OS |
 Recurrent GBM | I | 20 | Vaccine therapy in treating patients with recurrent glioblastoma | NCT03360708 | Recruiting | NA | Toxicity; tumor response; PFS; OS |
 Recurrent GBM | I | 40 | Pembrolizumab and a vaccine (ATL-DC) for the treatment of surgically accessible recurrent glioblastoma | NCT04201873 | Recruiting | Pembrolizumab and poly ICLC adjuvant | Toxicity; PFS; OS; Cell cycle-related signature; TIL density; TCR Clonality |
 GBM | I/II | 10 | Clinical study of a dendritic and glioma cells fusion vaccine with IL-12 for treatment-naïve GBM patients | NCT04388033 | Recruiting | IL-12 adjuvant | Toxicity; PFS; OS |
 HGG | I/II | 25 | Autologous dendritic cells and metronomic cyclophosphamide for relapsed high-grade gliomas in children and adolescents | NCT03879512 | Recruiting | Cyclophosphamide adjuvant | Toxicity; PFS; OS; Treg; CTL; cytokine |
 GBM | II | 87 | Dendritic cell cancer vaccine for high-grade glioma (GBM-Vax) | NCT01213407 | Completed | Trivax adjuvant | PFS; OS |
 GBM | II | 26 | Efficacy & safety of autologous dendritic cell vaccination in glioblastoma multiforme after complete surgical resection | NCT01006044 | Completed | NA | Toxicity; PFS; OS; humoral/cellular response |
 LGG | II | 18 | Vaccine for patients with newly diagnosed or recurrent low-grade glioma | NCT01635283 | Active, not recruiting | NA | PFS; OS |
 GBM | II | 50 | Dendritic cell-based tumor vaccine adjuvant immunotherapy of human glioblastoma multiforme | NCT02772094 | Active, not recruiting | NA | Toxicity; PFS; OS |
 Newly diagnosed  GBM | II | 136 | Efficiency of vaccination with lysate-loaded dendritic cells in patients with newly diagnosed glioblastoma (GlioVax) | NCT03395587 | Recruiting | NA | PFS; OS |
 Glioma | II | 60 | Dendritic cell vaccine for patients with brain tumors | NCT01204684 | Active, not recruiting | Poly-ICLC adjuvant | PFS; OS |